Ethnic disparities in presentation but not outcome in multiple myeloma patients: a multicenter retrospective study in Northern Israel

References

• Morris EV, Edwards CM. Bone marrow adiposity and multiple myeloma. Bone. 2019;118:42–46. doi:10.1016/j.bone.2018.03.011
   PubMed Web of Science ®Google Scholar
• Sergentanis TN, Zagouri F, Tsilimidos G, et al. Risk factors for multiple myeloma: a systematic review of meta-analyses. Clin Lymphoma Myeloma Leuk. 2015;15(10):563–577.e3. doi:10.1016/j.clml.2015.06.003
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107. doi:10.1002/ajh.26590
   PubMed Web of Science ®Google Scholar
• Steiner N, Göbel G, Suchecki P, et al. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients. Oncotarget. 2018;9(2):2344–2356. doi:10.18632/oncotarget.23412
   PubMedGoogle Scholar
• Smith CJ, Ambs S, Landgren O. Biological determinants of health disparities in multiple myeloma. Blood Cancer J. 2018;8(9):85. doi:10.1038/s41408-018-0118-z
   PubMedGoogle Scholar
• Landgren O, Graubard BI, Katzmann JA, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the national health and nutritional examination survey. Leukemia. 2014;28(7):1537–1542. doi:10.1038/leu.2014.34
   PubMed Web of Science ®Google Scholar
• Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among african American and white veterans in the United States. Blood. 2006;107(3):904–906. doi:10.1182/blood-2005-08-3449
   PubMed Web of Science ®Google Scholar
• Ailawadhi S, Aldoss IT, Yang D, et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012;158(1):91–98. doi:10.1111/j.1365-2141.2012.09124.x
   PubMed Web of Science ®Google Scholar
• Ailawadhi S, Jacobus S, Sexton R, et al. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the cooperative group clinical trials. Blood Cancer J. 2018;8(7):67. doi:10.1038/s41408-018-0102-7
   PubMed Web of Science ®Google Scholar
• Statistics C bureau of. Israel population [Internet]. 2021 [cited 2023 Jan 22]. Available from: https://www.cbs.gov.il/he/publications/doclib/2021/2.shnatonpopulation/st02_15x.pdf%0A%0A.
   Google Scholar
• Zidan J, Sikorsky N, Basher W, et al. Differences in pathological and clinical features of breast cancer in Arab as compared to Jewish women in Northern Israel. Int J Cancer. 2012;131(4):924–929. doi:10.1002/ijc.26431
   PubMed Web of Science ®Google Scholar
• Marinac CR, Ghobrial IM, Birmann BM, et al. Dissecting racial disparities in multiple myeloma. Blood Cancer J. 2020;10(2):19. doi:10.1038/s41408-020-0284-7
   PubMed Web of Science ®Google Scholar
• Sigurdardottir EE, Turesson I, Lund SH, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 2015;1(2):168–174. doi:10.1001/jamaoncol.2015.23
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–447. doi:10.1056/NEJMoa1300439
   PubMed Web of Science ®Google Scholar
• Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia. 2012;26(4):609–614. doi:10.1038/leu.2011.368
   PubMed Web of Science ®Google Scholar
• Landgren O, Graubard BI, Kumar S, et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the national health and nutrition examination survey. Blood Cancer J. 2017;7(10):e618–e618–e618. doi:10.1038/bcj.2017.97
   Google Scholar
• Ries L, Melbert D, Krapcho M. SEER cancer statistics review 1975–2012. Bethesda, MD NCI 2014;.
   Google Scholar
• Benjamin M, Reddy S, Brawley OW. Myeloma and race: a review of the literature. Cancer Metastasis Rev. 2003;22(1):87–93. doi:10.1023/a:1022268103136
   PubMed Web of Science ®Google Scholar
• SEER S. Explorer: an interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. 2019.
   Google Scholar
• Bhatnagar V, Wu Y, Goloubeva OG, et al. Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study. Cancer. 2015;121(7):1064–1070. doi:10.1002/cncr.29160
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Hill E, Hultcrantz M, et al. Molecular underpinnings of clinical disparity patterns in african American vs. Caucasian American multiple myeloma patients. Blood Cancer J. 2019;9(2):15. doi:10.1038/s41408-019-0177-9
   PubMedGoogle Scholar
• Pulte D, Redaniel MT, Brenner H, et al. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leuk Lymphoma. 2014;55(5):1083–1089. doi:10.3109/10428194.2013.827188
   PubMed Web of Science ®Google Scholar
• Manojlovic Z, Christofferson A, Liang WS, et al. Comprehensive molecular profiling of 718 multiple myelomas reveals significant differences in mutation frequencies between african and european descent cases. PLoS Genet. 2017;13(11):e1007087. doi:10.1371/journal.pgen.1007087
   PubMed Web of Science ®Google Scholar
• Costa LJ, Brill IK, Omel J, et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1(4):282–287. doi:10.1182/bloodadvances.2016002493
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood, J. Am. Soc. Hematol. 2010;116:5501–5506.
   Google Scholar
• Ailawadhi S, Bhatia K, Aulakh S, et al. Equal treatment and outcomes for everyone with multiple myeloma: are we there yet? Curr Hematol Malig Rep. 2017;12(4):309–316. doi:10.1007/s11899-017-0393-y
   PubMed Web of Science ®Google Scholar
• VanValkenburg ME, Pruitt GI, Brill IK, et al. Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features. Cancer Causes Control. 2016;27(1):81–91. doi:10.1007/s10552-015-0685-2
   PubMed Web of Science ®Google Scholar
• Brown LM, Linet MS, Greenberg RS, et al. Multiple myeloma and family history of cancer among blacks and whites in the US. Cancer Interdiscip. Int. J. Am. Cancer Soc. 1999;85:2385–2390.
   Google Scholar
• Fiala MA, Finney JD, Liu J, et al. Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. Leuk Lymphoma. 2015;56(9):2643–2649. doi:10.3109/10428194.2015.1011156
   PubMed Web of Science ®Google Scholar
• Byers TE, Wolf HJ, Bauer KR, et al. The impact of socioeconomic status on survival after cancer in the United States: findings from the national program of cancer registries patterns of care study. Cancer Interdiscip. Int. J. Am. Cancer Soc. 2008;113:582–591.
   Google Scholar
• Deng H, Zolekar A, Huang H-C, et al. Racial differences in the impact of socioeconomic status on cancer-specific survival in multiple myeloma. Cancer Res. 2021;81(13_Supplement):2628–2628. doi:10.1158/1538-7445.AM2021-2628
   Web of Science ®Google Scholar